GLP-1
Beyond the Holiday Joke: The Trillion-Dollar Economic Shift Fueled by GLP-1 Drugs
A satirical FT comment reveals a profound truth: weight-loss drugs are not just a health trend, but a seismic economic force reshaping global markets.
The Ozempic Economy: How Weight-Loss Drugs Are Reshaping Corporate Finance and Productivity
GLP-1 drugs like Ozempic are more than a health trend; they are a major economic force reshaping corporate finance, productivity, and investment strategies.
The Pill That Could Swallow the Market: Novo Nordisk’s Oral Wegovy and the New Frontier of Finance
Novo Nordisk’s US approval for an oral weight-loss pill ignites a new phase in its rivalry with Eli Lilly, reshaping the future of healthcare investing.
Beyond the Pill: Why Wegovy’s New Form is a Multi-Trillion Dollar Signal for the Global Economy
The US approval of a Wegovy pill is a game-changer, signaling major shifts for the stock market, the global economy, and the future of investing.
The Ozempic Price War: How a 71% Medicare Discount is Reshaping Healthcare Finance
A landmark 71% Medicare price cut on Ozempic and Wegovy signals a major shift in healthcare finance, impacting investors, the economy, and Big Pharma.
The Hundred-Billion-Dollar Pill: Inside Pfizer’s High-Stakes Gamble to Conquer the Weight-Loss Market
Pfizer is betting billions on an oral weight-loss pill to challenge Novo Nordisk and Eli Lilly’s injectable dominance in a market poised to hit $100B.
Pfizer’s $10 Billion Gambit: Winning the War for Metsera and the Future of Weight Loss
Pfizer outmaneuvered rival Novo Nordisk in a $10bn bidding war for weight-loss startup Metsera, a strategic move to combat its looming patent cliff.
Pharma’s High-Stakes Gamble: Inside the Pfizer vs. Novo Bidding War for a Weight-Loss Unicorn
A fierce bidding war erupts between Pfizer and Novo Nordisk for biotech firm Metsera, signaling a high-stakes battle for the future of the obesity drug market.
Pfizer’s $100 Billion Gamble: Inside the High-Stakes Battle for the Weight-Loss Drug Crown
Pfizer is playing hardball in the $100B weight-loss drug market, betting its future on a pill to challenge the injectable giants, Novo Nordisk and Eli Lilly.
The Rybelsus Revelation: Why One Chart Correction Unlocks Novo Nordisk’s True Value
A minor chart correction for Novo Nordisk reveals a major lesson in financial analysis, highlighting the crucial difference between its diabetes and obesity drugs.
The Ozempic Economy: How a Weight-Loss Shot is Reshaping Markets and Killing the Business Lunch
A new class of weight-loss drugs is shaking up the economy, impacting the stock market and threatening the future of the traditional business lunch.
The $600M Bet: How the Global Race for Weight-Loss Drugs is Rewriting the Rules of Biotech Investing and Tapping into China’s R&D Power
A US biotech’s $600M raise for weight-loss drugs reveals a key strategy: using China for faster, cheaper clinical trials, altering biotech investing.